Tau is researching, developing, and repositioning T-channel agents for the treatment of cancer. Tau’s strategy is to expand the reach of its novel Interlaced Therapy™ platform to all solid tumor cancers while simultaneously progressing in its drug development program. With this two-pronged approach, Tau hopes to transform the way cancer is treated.